Neurocrine Biosciences | NBIX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Cytokinetics USD 124.43M 2.17M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Exelixis USD 248.88M 4.82M 2026-06
Gilead Sciences USD 1.24B 1000K 2026-06
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Pfizer USD 5.7B 0 2026-06
Prothena USD 53.08M 756K 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Repligen USD 56.43M 28K 2026-06
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
Teva Pharmaceutical Industries USD 1.16B 1000K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06